Skip to main content
Premium Trial:

Request an Annual Quote

Harmonyx Test for Pain

Genetic testing company Harmonyx recently launched the Harmonyx Test for Pain, a $99 assay designed to provide personalized guidance to patients taking medicine for chronic or acute pain. The test uses a patient swab taken at a Harmonyx partner pharmacy, and examines the effects of eight genes on a patient's metabolism and efficacy of more than 20 pain mediciations, ranging from common over-the-counter drugs like ibuprofen and naproxen to frequently prescribed medications like morphine, methadone, hydrocodone, codeine, and oxycodone. Harmonyx provides a state-licensed physician to review each patient test request, and, if deemed medically appropriate, the test is ordered on behalf of the patient. Detailed results are returned to the pharmacist and treating physician in as little as 24 hours after the lab receives the test, Harmonyx said. Harmonyx, based in Memphis, Tennessee, is CAP accredited and CLIA certified.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.